Designed antimicrobial peptides for recurrent vulvovaginal candidiasis treatment
Riptide Bioscience Inc. has developed advanced antimicrobial peptides, RP556 and RP557, for treating recurrent vulvovaginal candidiasis. These peptides show potent activity against C. acnes with low toxicity, offering a novel solution resistant to existing drug resistance mechanisms.
Overview
Riptide Bioscience Inc. offers innovative designed antimicrobial peptides (dAMPs) for the treatment of recurrent vulvovaginal candidiasis. The therapeutic candidates, RP556 and RP557, demonstrate extremely potent activity against various strains of C. acnes with low minimum inhibitory concentrations (MIC) and a high therapeutic index. These peptides provide a significant advantage in treating infections, especially those resistant to traditional antibiotics.
Technical specifications
Key features:
- Potent Antimicrobial Activity: RP556 and RP557 exhibit MIC values of 2-8 µg/mL against C. acnes isolates.
- Low Toxicity: These peptides have a very low toxicity profile to eukaryotic cells, ensuring safety.
- High Therapeutic Index: RP556 has a therapeutic index of 130x, indicating effective dosing with minimal side effects.
- Resistance-Free Mode-of-Action: dAMPs are designed to bypass common resistance mechanisms, ensuring efficacy.
- Successful Preclinical Studies: Complete elimination of C. acnes infection in resistant dermal models has been demonstrated.
Technology readiness level
Currently at Technology Readiness Level 4, the program is in its late-preclinical stage, with successful IND-enabling studies concluded. Ongoing development includes formulation enhancements and preparation for a Phase 1 clinical trial. Riptide Bioscience Inc. is actively seeking development partners through licensing agreements to advance this promising treatment to the next stage of clinical trials.
About Riptide Bioscience Inc.
Riptide Bioscience Inc. is a biopharmaceutical company that develops engineered peptide therapeutics based on Host Defense Peptides (HDPs). By identifying the key structures of these naturally occurring proteins, the company uses proprietary methods to design synthetic peptides with significantly enhanced efficacy. These engineered peptides act through electrostatic attraction to microbial cell surfaces, allowing them to combat infections by penetrating bacterial biofilms that often resist conventional antibiotics. Additionally, the company has developed peptides designed to modulate inflammatory processes and target tumor-associated macrophages within the tumor microenvironment to inhibit tumor growth and metastasis.
These therapeutic candidates are intended to address significant medical challenges, including antibiotic-resistant infections, chronic inflammatory conditions, and various solid organ cancers. The company’s approach is supported by preclinical data from animal models and independent research, including collaborations with academic institutions and grants from organizations such as the National Cancer Institute, the National Eye Institute, and the Department of Defense. Riptide focuses on developing drug candidates for topical, subcutaneous, or other administrative applications in areas such as wound healing, pulmonary fibrosis, and oncology, while actively seeking pharmaceutical partnerships to advance its proprietary pipeline.
delivered to your inbox.